Exhibit 99.1 ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates Phase 2 REGEN-007 Positive Topline Results On July 8, 2025, ProKidney announced statistically and clinically significant topline results from the Phase 2 REGEN-007 study. Of note, in Group 1 (n=24), which replicated the rilparencel dosing schedule of the ongoing Phase 3 PROACT 1 study, kidney function stabilized. The annual decline in eGFR slope improved by 78%, from -5.8 in the pre-injection pe ...